Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

CSL (ASX:CSL) to build huge vaccine manufacturing centre

CSL Limited (ASX:CSL) is in the news this morning after news broke of a new manufacturing centre. 

CSL Limited (ASX: CSL) is in the news this morning after news broke of a new manufacturing centre.

What has been announced?

It has been reported in the media that CSL will build a new influenza vaccine manufacturing facility in Melbourne. It’ll be the largest in the southern hemisphere once complete.

CSL’s Seqirus will supposedly invest $800 million into making the facility. But there has also been a $1 billion, 12-year supply agreement with the government which will also help in acquiring land from the Victorian government near the Tullamarine Airport.

If you’re thinking this facility is going to be perfect for COVID-19, then you’ll be waiting a few years. The facility is expected to be fully operational by the middle of 2026. It’s expected to produce influenza pandemic vaccines, query fever vaccines and anti-venoms for animals like snakes, spiders and marine creatures.

This isn’t a brand new arrangement, it replaces an existing arrangement was due to expire in FY25, which is when the Seqirus Parkville facility will be retired.

It will be the only cell-based influenza vaccine manufacturing facility in the southern hemisphere, which will be used to help a shift away from ‘egg-based’ vaccines.

CSL CEO Paul Perreault said: “Providing safe and effective influenza vaccines is essential in securing our defences against serious public health threats.

Cell-based influenza vaccine technology offers many advantages over the existing process including being more scalable and offering faster production – particularly important in the case of influenza pandemics.

Time to buy CSL shares?

I think this agreement shows how important CSL is for the overall health of the country which is why it has such large demand for its facilities and products.

CSL is a high quality business and I think governments will think CSL’s services are more important in a post-COVID-19 world.

The healthcare giant could get a boost if it turns out that we need to take regular COVID-19 vaccines to (hopefully) maintain immunity.

At the current CSL share price I think I’d be willing to make a small investment and buy more on weakness, but there are other ASX growth shares I’d buy first like Pushpay Holdings Ltd (ASX: PPH).

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content